SCIENTIFIC PROGRAMME
Thursday, April 3, 2025
08.30 Registration Opens
​​
09.30 - 09.40 Welcome Addresses
09.30 – 09.35
Welcome Address by the conference president Michael von Bergwelt, Munich, Germany
09.35 – 09.40
Welcome Adddress on behalf of the Ludwig Maximilians University by Stefan Endres, Munich, Germany
​
09.40 - 11.10 Plenary Session 1: Tumor Immunology Inside: Novel Players
Chair: Christoph Zielinski, Vienna, Austria & Niroshana Anandasabapathy, New York, NY, United States
09.40 – 10.10
01.01. Immune regulation of CCR7+ dendritic cells at tumor sites
Béatrice Zitti, Geneva, Switzerland
10.10 – 10.40
01.02. Dendritic cells as orchestrators of cancer immunity
Niroshana Anandasabapathy, New York, NY, United States
10.40 – 11.10
01.03. Tregs in the cancer environment
Eliane Piaggio, Paris, France
​
11.10 - 11.40 Coffee Break
​
11.40 - 13.10 Plenary Session 2: Expect the Unexpected: Factors Influencing Immune Therapies
Chair: Lucie Heinzerling, Munich, Germany & Tanja de Gruijl, Amsterdam, Netherlands​
​
11.40 - 12.10
02.01. The influence of circadian rhythm on IO agent efficacy
Christoph Scheiermann, Geneva, Switzerland
12.10 - 12.40
02.02. Androgen influence on immunotherapy
Megan Ruhland, Portland, OR, United States
12.40 - 13.10
02.03. Local production of glucocorticoids in cancer and its therapeutic relevance
Matthew Taves, Bethesda, MD, United States
​
13.10 - 13.20 Company Pitch | Click to View more
​
13.20 - 15.00 Lunch & Poster Viewing
​
15.00 - 17.00 Plenary Session 3: New Targets and New Leads
Chair: Andrea Schmidts, Munich, Germany & Pedro Romero, Lausanne, Switzerland​
​
15.00 - 15.30
03.01. Proteostatic Stress Response as Novel Opportunity for Cancer Immunotherapy
Zihai Li, Columbus, OH, United States
15.30 - 16.00
03.02. MultiOmics in pushing the frontiers in understanding the tumor microenvironment: Single cell resolution imaging
Matteo Iannacone, Milan, Italy
16.00 – 16.15
03.03. KLK4 cleaves CXCR3 chemokines and confers immune escape and resistance to cancer immunotherapy Tobias Dreyer, Munich, Germany
​
16.15 – 16.30
03.04. Exploring immunotherapy resistance in primary and metastatic oral cancer using organoid technology
Lili Szabó, Würzburg, Germany
​​
16.30 – 16.45
03.05. Targeting PD-1 with self-delivering RNAi: preclinical advances and ongoing clinical evaluation in intratumoral Immunotherapy
Melissa Maxwell, Marlborough, United States
​
16.45 – 17.00
03.06. Neoadjuvant chemoradiotherapy with ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial
Michael Bergmann, Vienna, Austria
​
17.00 - 18.00 Plenary Session 4: Polyspecific Antibody Derivatives
​Chair: Juliane Walz, Tübingen, Germany & Michael Bergmann, Vienna, Austria
​
17.00-17.30
04.01. TCR and TCR mimetics x CD3 bispecific antibodies, challenges and opportunities
José Saro Suarez, Geneva, Switzerland
17.30-18.00
04.02. Bispecific gamma-delta T-cell engagers (Gammabodies) against cancer
Hans van der Vliet, Amsterdam, The Netherlands
​
​
18.00 - 20.00 Networking Event and Poster Viewing (at the venue)
​
Friday, April 4, 2025
​
​08.30 – 09.30 Plenary Session 5: Pro and Con: Local vs Systemic Immunotherapy
​Chair: Mascha Binder, Basel, Switzerland & Niels Halama, Heidelberg, Germany
​
08.30 – 09.00
05.01. Pro-local immunotherapies
Louisa von Baumgarten, Munich, Germany
09.00 – 09.30
05.02. Pro systemic immunotherapy
Mascha Binder, Basel, Switzerland
​
09.30 – 10.30 Plenary Session 6: Playing with the Devil: Nociception in Cancer Immunotherapy
​Chair: Louisa von Baumgarten, Munich, Germany & Martin Kerschensteiner, Munich, Germany
​
09.30 – 10.00
06.01. Triggering alpha2adrenergic receptors for tumor rejection
Jingjing Zhu, Louvain, Belgium
10.00 – 10.30
06.02. Neuro-immune regulation of ILC function in anti-tumor immunity
Camilla Jandus, Geneva, Switzerland
​
10.30 – 11.00 Coffee Break
​
11.00 – 12.30 Plenary Session 7: Immune Monitoring – Omics Technology
​Chair: Carolin Mogler, Munich, Germany & Jürgen Ruland, Munich, Germany
​
11.00 – 11.30
07.01. Spatial profiling of the immune contexture in cancer: a novel translational way to attack ‘cold’ tumors
Niels Halama, Heidelberg, Germany
11.30 – 12.00
07.02. Resolving the HLA-ligandome in cancer
Juliane Walz, Tübingen, Germany
12.00 – 12.30
07.03. Liquid immunotranscriptomics-derived biomarkers for monitoring response to immunotherapy in metastatic cancer
Pedro Romero, Lausanne, Switzerland
​
12.30 - 13.00 Satellite Symposium | Click to View the Detailed Programme
Chair: Sebastian Kobold, Munich, Germany
​​
13.00 – 14.30 Lunch & Poster Viewing
​
14.30 – 15.15 Plenary Session 8: ITOC 11 Lifetime Achievement Award
Chair: Sebastian Kobold, Munich, Germany & Michael von Bergwelt, Munich, Germany
08.01. Advancing Cancer Therapy: From Cancer Immunoediting to Personalized Cancer Vaccines
Robert D. Schreiber, St. Louis, MO, United States
​
15.15 - 16.30 Plenary Session 9: Advancing Cancer Vaccines
​Chair: Eric Tartour, Paris, France & Chong Xian Pan, Boston, MA, United States
​
15.15 – 15.45
09.01. Neoantigen selection in tumor and lessons from flu
Paul G. Thomas, Memphis, TN, United States
15.45 – 16.15
09.02. Lightening strikes: irreversible electroporation as a means of in vivo vaccination in Pancreatic Ductal Adenocarcinoma
Tanja de Gruijl, Amsterdam, The Netherlands
16.15 – 16.30
09.03. Preliminary immunogenicity results from the dose escalation phase of a first-in-human study of the mRNA-based
cancer vaccine CVGBM in patients with newly diagnosed MGMT-unmethylated glioblastoma
Sandra Lazarro, Tübingen, Germany
​
16.30 - 17.00 Coffee Break
17.00 - 18.00 Plenary Session 10: Young Researcher Session (from submitted abstracts)
Chair: Stefan Endres, Munich, Germany & Ralf Jungmann, Munich, Germany
​
17.00 – 17.15
10.01. CD44v6-specific CAR-NK cells: a novel approach to precision medicine in bladder cancer
Iris Lodewijk, Madrid, Spain
​
17.15 – 17.30
10.02. Targeting CSF1R+ myelo-monocytic cells enhances CAR-T cell response in B cell lymphoma
David Stahl, Cologne, Germany
​
17.30 – 17.45
10.03. Immunosensitizing effect of TLR agonist combination for the treatment of cold tumors
Thomas Morin, Dijon, France
​
17.45 – 18.00
10.04. Adapter P329G-directed CAR T cells for modular targeting of lung cancer
Sophia Stock, Munich, Germany
​
18.00 - 19.00 Poster Viewing with Presenters
​
19.15 ITOC 11 Conference Dinner
Saturday, April 5, 2025
​
08.00 – 09.00 Plenary Session 11: What Cellular Therapies Need to Work
​Chair: Hendrik Poeck, Regensburg, Germany & Roland Ullrich, Cologne, Germany
​
08.00 – 08.30
11.01. The role of preconditioning in T cell therapy
Michal Besser, Tel Aviv, Israel
08.30 – 09.00
11.02. The role of myeloid cells in CAR T cell failure
Camille Bigenwald, Villejuif, France
​
09.00 – 10.30 Plenary Session 12 Engineering novel Cellular Immunotherapies
​Chair: Marion Subklewe, Munich, Germany & Dirk Busch, Munich, Germany
​
09.00 – 09.30
12.01. Novel targets of TCR therapies
Johanna Olweus, Oslo, Norway
09.30 – 10.00
12.02. Adoptive Cell Therapy, ways to enhance them
Sabine Heitzeneder, Stanford, CA, United States
10.00 – 10.30
12.03. RORing cancer with novel CAR T cells
Michael Hudecek, Würzburg, Germany
​
10.30 – 11.00 Coffee Break
​
11.00 – 12.45 Plenary Session 13: Advancing Cellular Therapies with Combinations
​Chair: Ulrich Jäger, Vienna, Austria & Johanna Olweus, Oslo, Norway
​
11.00 – 11.30
13.01. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors
Andreas Mackensen, Erlangen, Germany
11.30 – 12.00
13.02. Targeting TGFbeta-activated kinase-1 activation in microglia to reduce neurotoxicities of CAR T cell therapies
Robert Zeiser, Freiburg, Germany
​
12.00 – 12.15
13.03. Ablation of FAS confers allogeneic CD3- CAR T cells with resistance to rejection by T cells and natural killer cells
Silvia Menegatti, Suresnes, France
​
12.15 – 12.30
13.04. SIlencing BRD4 to increase NK cell activity for adoptive cell therapy: a novel self-delivering RNAi approach
Melissa Maxwell, Marlborough, United States
​
12.30 – 12.45
13.05. Autocrine glucocorticoid signaling in hormonally active cancers induces antigen expression for CAR-T cell therapy
Marc Schauer, Würzburg, Germany
​
12.45 – 13.15 Plenary Session 14: Best Poster Awards & Closing Remarks
​Chair: Sebastian Kobold, Munich, Germany & Michael von Bergwelt, Munich, Germany
​
13.15 – 14.15 Lunch & Farewell
​
​